ESR1 and breast cancer: Traditionally, the expression of immunohistochemical markers, including the estrogen receptor (ER), the progesterone receptor (PR) and the epidermal growth factor receptor 2 (HER2), together with clinicopathological information have been used to classify breast cancer and to predict disease outcome4, 5.